-
Je něco špatně v tomto záznamu ?
Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report
M. Durila, J. Berousek, V. Vlasakova, T. Vymazal
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu kazuistiky, časopisecké články
Grantová podpora
No. 00064203
Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
No. 00064203
Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
No. 00064203
Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
No. 00064203
Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
NLK
BioMedCentral
od 2006-12-01
BioMedCentral Open Access
od 2006
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2007-01-04
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
Springer Nature OA/Free Journals
od 2006-12-01
- MeSH
- antikoagulancia škodlivé účinky MeSH
- enoxaparin MeSH
- heparin nízkomolekulární MeSH
- heparin škodlivé účinky MeSH
- krvácení etiologie MeSH
- lidé MeSH
- mimotělní membránová oxygenace * škodlivé účinky MeSH
- trombóza * etiologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
BACKGROUND: Unfractionated heparin is used worldwide as a standard anticoagulation therapy for extracorporeal membrane oxygenation (ECMO) machines. However, its use brings about significant bleeding and thrombotic complications for critically ill patients. This case report shows that low molecular weight heparin together with ECMO-produced primary haemostasis pathology can be used as an alternative way of ECMO anticoagulation. CASE PRESENTATION: This paper presents the case of a patient with respiratory failure who subsequently suffered from cardiac failure and spent 94 days on combined V-V and V-A ECMO devices (two ECMO devices running simultaneously on one patient) with intravenous enoxaparin used instead of unfractionated heparin anticoagulation. No life-threatening bleeding/thrombotic events happened during this period, nor did any technical problems with ECMO occur. CONCLUSIONS: In this case report, continuous intravenous low molecular weight heparin anticoagulation was used as a safe alternative to ECMO anticoagulation.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010455
- 003
- CZ-PrNML
- 005
- 20230801132434.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13019-023-02226-0 $2 doi
- 035 __
- $a (PubMed)37041623
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Durila, Miroslav $u Department of Anaesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic. miroslav.durila@fnmotol.cz $1 https://orcid.org/0000000295158235
- 245 10
- $a Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report / $c M. Durila, J. Berousek, V. Vlasakova, T. Vymazal
- 520 9_
- $a BACKGROUND: Unfractionated heparin is used worldwide as a standard anticoagulation therapy for extracorporeal membrane oxygenation (ECMO) machines. However, its use brings about significant bleeding and thrombotic complications for critically ill patients. This case report shows that low molecular weight heparin together with ECMO-produced primary haemostasis pathology can be used as an alternative way of ECMO anticoagulation. CASE PRESENTATION: This paper presents the case of a patient with respiratory failure who subsequently suffered from cardiac failure and spent 94 days on combined V-V and V-A ECMO devices (two ECMO devices running simultaneously on one patient) with intravenous enoxaparin used instead of unfractionated heparin anticoagulation. No life-threatening bleeding/thrombotic events happened during this period, nor did any technical problems with ECMO occur. CONCLUSIONS: In this case report, continuous intravenous low molecular weight heparin anticoagulation was used as a safe alternative to ECMO anticoagulation.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a enoxaparin $7 D017984
- 650 _2
- $a heparin $x škodlivé účinky $7 D006493
- 650 _2
- $a antikoagulancia $x škodlivé účinky $7 D000925
- 650 12
- $a mimotělní membránová oxygenace $x škodlivé účinky $7 D015199
- 650 _2
- $a krvácení $x etiologie $7 D006470
- 650 _2
- $a heparin nízkomolekulární $7 D006495
- 650 12
- $a trombóza $x etiologie $7 D013927
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Berousek, Jan $u Department of Anaesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic
- 700 1_
- $a Vlasakova, Vlasta $u Department of Anaesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic
- 700 1_
- $a Vymazal, Tomas $u Department of Anaesthesiology and Intensive Care Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06, Prague 5, Czech Republic
- 773 0_
- $w MED00163181 $t Journal of cardiothoracic surgery $x 1749-8090 $g Roč. 18, č. 1 (2023), s. 137
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37041623 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132431 $b ABA008
- 999 __
- $a ok $b bmc $g 1963087 $s 1196720
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 18 $c 1 $d 137 $e 20230411 $i 1749-8090 $m Journal of cardiothoracic surgery $n J Cardiothorac Surg $x MED00163181
- GRA __
- $a No. 00064203 $p Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
- GRA __
- $a No. 00064203 $p Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
- GRA __
- $a No. 00064203 $p Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
- GRA __
- $a No. 00064203 $p Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
- LZP __
- $a Pubmed-20230718